Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#2 clBTC clBTC +12.15%
#3 OpenEden OpenEden +11.48%
#4 BasedHype BasedHype +11.14%
#5 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.73%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +8.41%
#7 Mantle Staked Ether Mantle Staked Ether +8.34%
#8 Mantle Restaked ETH Mantle Restaked ETH +8.01%
#9 MarsCoin MarsCoin +6.65%
#10 EfficientFrontier EfficientFrontier +4.93%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Avivagen Inc. Avivagen Inc.

Avivagen Inc.

VIV
Rank in Stocks #40244
Avivagen Inc. is a life sciences enterprise that invents and sells specialized... Avivagen Inc. is a life sciences enterprise that invents and sells specialized products, primarily for animal feed, aimed at bolstering the immune systems of livestock. These solutions are designed to enhance animals' health, leading to improved growth and overall productivity. The company's diverse product lineup features OxC-beta Livestock, a crucial premix for farm animal diets. Beyond agriculture, Avivagen also manufactures health supplements such as Vivamune and Dr. Tobias-branded chews for dogs, along with the Dr. Tobias Beta blend, formulated to support human immunity. Established in 2005 and based in Ottawa, Canada, Avivagen Inc. distributes its offerings across numerous international markets, including the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, Brazil, and Malaysia.
Share Price
$0.00368316
Last synced: 2024-03-04
Market Cap
$199.43K
Change (1 day)
0.05%
Change (1 year)
0.00%
Country
CA
Trade Avivagen Inc. (VIV)

Category

Healthcare
Revenue for Avivagen Inc. (VIV)
Revenue in Aug 2026 TTM: 0
According to Avivagen Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Avivagen Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B -
IN